This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.
Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings
by Zacks Equity Research
Herbalife (HLF) is likely to gain from its direct-selling network, product portfolio and solid volumes. However, unfavorable currency movements and stiff competition may hurt the bottom line.
Why Jazz (JAZZ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
by Zacks Equity Research
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
by Zacks Equity Research
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Jazz (JAZZ) Increases Share Buyback Authorization by $400M
by Zacks Equity Research
Jazz's (JAZZ) board sanctions a raise in its share buyback authorization by $400 million.
Why Is Jazz (JAZZ) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ)
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.
Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 7.51% and -2.65%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
by Zacks Equity Research
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
5 Low Price-to-Book Stocks to Buy in a Volatile Market
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Is Jazz Pharmaceuticals a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?
by Zacks Equity Research
Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?
by Zacks Equity Research
Workiva (WK) continues to focus on developing its flagship product, Wdesk cloud platform, which continues to gain traction.
Zillow Group (ZG) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Zillow Group (ZG) to benefit from strong growth of it's Premier Agent Business. We expect the company to gain from increasing traffic at its mobile apps and websites, strong rental demand and MLS partnerships.
ANSYS (ANSS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Synergies from acquisitions are enabling ANSYS(ANSS) to bring innovative solutions to the market and also to enhance its foothold in the competitive simulations market.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.